National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN Enzalutamide Research Grant Opportunity Submit by April 27, 2015
Study Proposal Submission-NCCN RMS
ORP Recent News
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
Specialized Imaging Research Consortium™ (SIRC)
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Trastuzumab Added to Esophageal and Gastric Cancer Guidelines

The NCCN Clinical Practice Guidelines in Oncology™ for Esophageal Cancer and the NCCN Clinical Practice Guidelines in Oncology™ for Gastric Cancer have been updated and published. Both Guidelines are now available in v.1.2010.

Trastuzumab in combination with systemic chemotherapy was added to the Esophageal and Gastric Cancer Guidelines as an option for the treatment of patients with advanced esophageal cancer, gastric cancer, or GE junction adenocarcinoma that is HER-2-positive as determined by a standardized method.